Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating HBI-8000 in combination with nivolumab for melanoma, renal cell carcinoma, and non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-09Clinical Trial Results: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study of pegylated IL-10 (pegilodecakin) in adults with advanced solid tumors; results from a first-in-human trial assessing safety …
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-18Clinical Trial Results: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma [Phase 1, Phase 2]
Clinical trial results for a recombinant vaccinia virus in combination with cemiplimab in renal cell carcinoma have been completed, with res…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating pembrolizumab plus lenvatinib for brain metastases from melanoma or renal cell carcinoma; study terminated with res…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) [Phase 3]
Phase 3 clinical study evaluating belzutifan and zanzalintinib in recurrent renal cell carcinoma after adjuvant therapy is in recruitment.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
A National Cancer Institute–sponsored clinical trial is conducting comprehensive omics analyses of pediatric and adult solid tumors and esta…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 [Phase 2]
An ongoing Phase 2 trial evaluating the WEE1 inhibitor adavosertib (AZD1775) in advanced solid tumors with SETD2 mutations, including clear …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma [Phase 1, Phase 2]
Orellanine is being studied in metastatic renal cell carcinoma (clear-cell and papillary) in Phase 1/Phase 2, with patient recruitment curre…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) [Phase 3]
Phase 3 trial LS-034 evaluating belzutifan (MK-6482) in combination with zanzalintinib for renal cell carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) [Phase 3]
Extension study update for participants in Phase 3 trials of Belzutifan (MK-6482-043 / LITESPARK-043) with ongoing recruitment.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers [Phase 1]
Phase 1 clinical trial update evaluating DS3201 in combination with ipilimumab for metastatic prostate, urothelial, and renal cell cancers.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Use of Tracking Devices to Locate Abnormalities During Invasive Procedures [NA]
NIH-sponsored clinical trial update describes a study evaluating tracking devices to locate abnormalities during invasive procedures, with e…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors [Phase 2]
Phase 2 clinical trial update of ceralasertib (AZD6738) alone and in combination with olaparib or durvalumab in various solid tumors; the st…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
AstraZeneca is conducting a Phase 1/2 trial to evaluate the safety of AZD6750 in adults with select advanced or metastatic solid tumors; the…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Multimodal Machine Learning Characterization of Solid Tumors
This ClinicalTrials.gov update describes a multimodal machine learning study to characterize solid tumors, listing prostate cancer, hepatoce…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors [Phase 2]
This clinical trial update outlines a Phase 2 study assessing the combination of nivolumab, ipilimumab, and cabozantinib for various rare ge…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Aerosolized Aldesleukin in Treating Patients With Lung Metastases [Phase 1]
Phase 1 study evaluating aerosolized aldesleukin (interleukin-2) in patients with cancers that have metastasized to the lung, including mela…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) [Phase 2]
Phase II trial evaluating evolocumab plus nivolumab to bolster immunotherapy in metastatic renal cell carcinoma. The study is active but not…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Study of DCC-2812 in Participants With Advanced Genitourinary Cancers [Phase 1]
This clinical trial update reports that a Phase 1 study of DCC-2812 in advanced genitourinary cancers (renal cell carcinoma, urothelial carc…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of Bevacizumab, Erlotinib, and Atezolizumab for advanced renal cell carcinoma. The study i…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 trial examining perioperative lenvatinib with pembrolizumab in locally advanced nonmetastatic clear cell renal cell carcinoma; resul…